PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Actual Study Completion Date :September 17, 2020
Primary Outcome Measures :Clinical Benefit Rate (CBR) at 24 weeks of PDR001+LAG525 by tumor type in multiple solid tumors and lymphoma [ Time Frame: 24 weeks ]Clinical Benefit Rate (CBR) is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) and Stable Disease.
28 weeks since completion of trial.....
PDR001 Plus LAG525 for Patients With Advanced Solid and...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
0.008(2.21%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.889M | 5.400M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 211388 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 162595 | 24 |
View Market Depth
| Last trade - 15.22pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |